Clinical Trials Logo

Clinical Trial Summary

The aim is to establish the maximal tolerated dose of AZD3355 for the selection of doses in the up-coming studies. This will be done by comparing single and repeated doses of AZD3355 to placebo ("inactive substance"). Safety and tolerability variables will be closely monitored throughout the study.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT00757419
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 1
Start date September 2008
Completion date December 2008

See also
  Status Clinical Trial Phase
Completed NCT05634187 - One-stop-shop Endoscopy in Reflux-patients: Evaluation of ENT and GI Features
Recruiting NCT05004155 - Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
Not yet recruiting NCT06129474 - Deprescribing Inappropriate Proton Pump Inhibitors N/A
Recruiting NCT05051475 - Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus N/A
Completed NCT06381583 - A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma